Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5581703 | Clinical Lymphoma Myeloma and Leukemia | 2017 | 6 Pages |
Abstract
In patients with newly diagnosed DLBCL, PET-CT is accurate in detecting BMI by DLBCL. Although PET-CT has a very high negative predictive value for BMI, it overestimates the number of cases with marrow involvement by DLBCL. In clinical practice, routine BMAB may no longer be necessary for all patients with DLBCL who are staged by PET-CT, unless the results would change both staging and therapy. The prognostic implication of BMI identified by PET-CT compared with BMAB remains unknown. Whether a PET-CT precludes the need for a BMAB in patients with DLBCL remains to be evaluated in a prospective study.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Prakash Vishnu, Andrew Wingerson, Marie Lee, Margaret T. Mandelson, David M. Aboulafia,